Influence of ethnicity on the diagnostic accuracy of plasma p-tau217 for the identification of Alzheimer's disease: A consecutive mixed memory clinic cohort study

被引：0

作者：

Kjaergaard, Daniel ^{[1
]}

Nielsen, T. Rune ^{[1
,2
]}

Stomrud, Erik ^{[3
,4
]}

Palmqvist, Sebastian ^{[3
,4
]}

Bali, Divya ^{[3
]}

Dolado, Anna Orduna ^{[3
]}

Janelidze, Shorena ^{[3
]}

Hansson, Oskar ^{[3
]}

Waldemar, Gunhild ^{[1
,5
]}

Simonsen, Anja Hviid ^{[1
]}

机构：

[1] Copenhagen Univ Hosp Rigshosp, Danish Dementia Res Ctr, Neurosci Ctr, Dept Neurol, Copenhagen, Denmark

[2] Univ Copenhagen, Dept Psychol, Copenhagen, Denmark

[3] Lund Univ, Dept Clin Sci Malmo, Clin Memory Res Unit, Lund, Sweden

[4] Skane Univ Hosp, Memory Clin, Malmo, Sweden

[5] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark

来源：

ALZHEIMERS & DEMENTIA | 2025年 / 21卷 / 06期

基金：

欧洲研究理事会; 瑞典研究理事会;

关键词：

Alzheimer's disease; amyloid pathology; blood-based biomarkers; cerebrospinal fluid; confounders; dementia; diversity; ethnicity; phosphorylated tau; plasma biomarkers; racial groups; ASSOCIATION WORKGROUPS; NATIONAL INSTITUTE; TAU; DEMENTIA; CRITERIA; RECOMMENDATIONS; GUIDELINES; HAPLOTYPE; VARIANT; RISK;

D O I：

10.1002/alz.70315

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

INTRODUCTION: Blood-based biomarkers have demonstrated high accuracy for identifying Alzheimer's disease (AD) pathology. However, the lack of representative cohorts creates a knowledge gap regarding their real-world applicability. We examined the influence of ethnicity on the diagnostic accuracy of plasma tau phosphorylated at threonine 217 (p-tau217) in identifying AD. METHODS: A total of 1170 mixed memory clinic patients originating from 91 different countries were included. Cerebrospinal fluid or amyloid positron emission tomography supplemented the diagnostic evaluation for 539 patients. Plasma was analyzed for p-tau217. RESULTS: Plasma p-tau217 concentrations did not differ between ethnic groups, and there was no influence of ethnicity on the diagnostic accuracy of plasma p-tau217. Plasma p-tau217 demonstrated strong discriminative ability for AD and AD-pathology in our ethnically diverse cohort. DISCUSSION: Our study suggests that ethnicity does not influence the diagnostic accuracy of plasma p-tau217. Nonetheless, medical conditions influencing plasma biomarkers may disproportionally affect minoritized groups because of social determinants of health.

引用

页数：12

共 72 条

[1]

Sims J.R., Zimmer J.A., Evans C.D., Et al., Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial, JAMA, 330, pp. 512-527, (2023)

[2]

Budd Haeberlein S., Aisen P.S., Barkhof F., Et al., Two randomized phase 3 studies of aducanumab in early Alzheimer's disease, J Prev Alzheimers Dis, 9, pp. 197-210, (2022)

[3]

van Dyck C.H., Swanson C.J., Aisen P., Et al., Lecanemab in early Alzheimer's disease, N Engl J Med, 388, pp. 9-21, (2023)

[4]

Mintun M.A., Lo A.C., Duggan Evans C., Et al., Donanemab in early Alzheimer's disease, N Engl J Med, 384, pp. 1691-1704, (2021)

[5]

Schindler S.E., Galasko D., Pereira A.C., Et al., Acceptable performance of blood biomarker tests of amyloid pathology—recommendations from the Global CEO Initiative on Alzheimer's Disease, Nat Rev Neurol, 20, pp. 426-439, (2024)

[6]

Bonomi S., Gupta M.R., Schindler S.E., Inadequate reimbursement for lumbar puncture is a potential barrier to accessing new Alzheimer's disease treatments, Alzheimers Dement, 19, pp. 5849-5851, (2023)

[7]

Verberk I.M.W., Thijssen E., Koelewijn J., Et al., Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology, Alzheimers Res Ther, 12, (2020)

[8]

Verberk I.M.W., Laarhuis M.B., van den Bosch K.A., Et al., Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study, Lancet Healthy Longev, 2, pp. e87-e95, (2021)

[9]

Pereira J.B., Janelidze S., Stomrud E., Et al., Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects, Brain, 144, pp. 2826-2836, (2021)

[10]

Pereira J.B., Janelidze S., Smith R., Et al., Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease, Brain, 144, pp. 3505-3516, (2021)

← 1 2 3 4 5 6 7 8 →